3Eichman JD, Robinson JR. Mechanistic studies on effervescent induced permeability enhancement[ J]. Pharm Res, 1998, 15: 925 - 930
4Eichman JD, Yassin AE - DB, Robinson JR. The influence of in vivo carbonation on GI physiological processes and drug permeabihty[ J]. Eur J Pharm Biopharm, 1997, 44:33 -38
5Darwish M, Tempero K, Kirby M, et al. Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers[ J]. Clin Pharmacokinet, 2005, 44 : 1279 - 1286
6Durfee S, Messina J, Khankari R. Fentanyl effervescent buccal tablets: enhanced buccal absorption [ J ]. Am J Drug Deliv, 2006, 4:1 -5
7Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non - malignant diseases: a review of prevalence, characteristics and mechanism[ J]. Eur J Pain, 2005, 9 : 195 - 206
8Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment [ J ]. Cancer Treat Rev, 1998, 24 : 425 - 432
9Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain[J]. Pain, 1999, 81 : 129 - 134
10Darwish M, Kirby M, Robertson P, et al. Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics[ J]. Clin Pharmacokinet, 2006, 45 (8) : 843 -850
